<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Insufficient migration and activation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> specific effector T cells in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> is one of the main reasons for inadequate host anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> immune response </plain></SENT>
<SENT sid="1" pm="."><plain>External radiation seems to induce <z:mp ids='MP_0001845'>inflammation</z:mp> and activate the immune response </plain></SENT>
<SENT sid="2" pm="."><plain>This phase I/II clinical trial aims to evaluate whether low dose single fraction radiotherapy can improve T cell associated antitumor immune response in patients with colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS/DESIGN: This is an investigator-initiated, prospective randomised, 4-armed, controlled Phase I/II trial </plain></SENT>
<SENT sid="4" pm="."><plain>Patients undergoing elective hepatic resection due to <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> will be enrolled in the study </plain></SENT>
<SENT sid="5" pm="."><plain>Patients will receive 0 Gy, 0.5 Gy, 2 Gy or 5 Gy radiation targeted to their <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Radiation will be applied by external beam radiotherapy using a 6 MV linear accelerator (Linac) with intensity modulated radiotherapy (IMRT) technique two days prior to surgical resection </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients admitted to the Department of General-, Visceral-, and Transplantion Surgery, University of Heidelberg for elective hepatic resection are consecutively screened for eligibility into this trial, and written informed consent is obtained before inclusion </plain></SENT>
<SENT sid="8" pm="."><plain>The primary objective is to assess the effect of active local external beam radiation dose on, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> infiltrating T cells as a surrogate parameter for antitumor activity </plain></SENT>
<SENT sid="9" pm="."><plain>Secondary objectives include radiogenic treatment toxicity, postoperative morbidity and mortality, local <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> control and recurrence patterns, survival and quality of life </plain></SENT>
<SENT sid="10" pm="."><plain>Furthermore, frequencies of systemic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> reactive T cells in blood and bone marrow will be correlated with clinical outcome </plain></SENT>
<SENT sid="11" pm="."><plain>DISCUSSION: This is a randomized controlled patient blinded trial to assess the safety and efficiency of low dose radiotherapy on <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> infiltrating T cells and thus potentially enhance the antitumor immune response </plain></SENT>
<SENT sid="12" pm="."><plain>TRIAL REGISTRATION: ClinicalTrials.gov: NCT01191632 </plain></SENT>
</text></document>